These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 11604047)

  • 1. Role of anti-interleukin-2 receptor antibodies in kidney transplantation.
    Cibrik DM; Kaplan B; Meier-Kriesche HU
    BioDrugs; 2001; 15(10):655-66. PubMed ID: 11604047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A
    Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review.
    Nashan B
    BioDrugs; 2005; 19(1):39-46. PubMed ID: 15691216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction immunotherapy with IL-2Ra monoclonal antibody in kidney transplantation.
    Ahsan N
    Minerva Urol Nefrol; 2003 Mar; 55(1):67-79. PubMed ID: 12773968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a review.
    Sandrini S
    Clin Transplant; 2005 Dec; 19(6):705-10. PubMed ID: 16313313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
    Hong JC; Kahan BD
    Transplantation; 2001 May; 71(9):1320-8. PubMed ID: 11397971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monoclonal interleukin-2 receptor antibodies and their use in clinical kidney transplantation: basiliximab and daclizumab].
    Madsen M; Svendsen UG
    Ugeskr Laeger; 2000 Oct; 162(42):5648-52. PubMed ID: 11059309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance immunosuppression with intermittent intravenous IL-2 receptor antibody therapy in renal transplant recipients.
    Gabardi S; Catella J; Martin ST; Perrone R; Chandraker A; Magee CC; McDevitt-Potter LM
    Ann Pharmacother; 2011 Sep; 45(9):e48. PubMed ID: 21811001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New monoclonal antibodies in renal transplantation.
    Vincenti F
    Minerva Urol Nefrol; 2003 Mar; 55(1):57-66. PubMed ID: 12773967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of anti-IL-2 receptor in high-risk kidney transplant patients.
    Jirasiritham S; Sumethkul V; Mavichak V; Lertsithichai P; Jirasiritham S
    Transplant Proc; 2004 Sep; 36(7):2110-2. PubMed ID: 15518764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation.
    Di Filippo S
    Pediatr Transplant; 2005 Jun; 9(3):373-80. PubMed ID: 15910396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interleukin-2 receptor blockers in renal transplantation].
    Basić-Jukić N; Bubić-Filipi L; Danić A; Pasini J; Kes P
    Acta Med Croatica; 2004; 58(5):395-9. PubMed ID: 15756806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune reactivity of renal transplant recipients receiving interleukin-2 receptor antagonists during the early posttransplant period.
    Zivčić-Ćosić S; Lisjak J; Rački S; Trobonjača Z
    Int Urol Nephrol; 2014 Jan; 46(1):191-200. PubMed ID: 23515930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring of T-cell subsets in patients treated with anti-CD 25 antibody.
    Praditpornsilpa K; Avihingsanon Y; Kupatawintu P; Songpanich S; Pisitkul T; Kansanabuch T; Eiam-Ong S; Chusil S; O-Charoen R; Tungsanga K
    Transplant Proc; 2004 Mar; 36(2 Suppl):487S-491S. PubMed ID: 15041394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
    Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
    Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of monoclonal antibodies in renal transplantation.
    van den Hoogen MW; Hilbrands LB
    Immunotherapy; 2011 Jul; 3(7):871-80. PubMed ID: 21751955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB; Mendoza TR; Esmeraldo RM; Oliveira ML; Paes FJ; Silva Junior GB; Daher EF
    Int Immunopharmacol; 2011 Nov; 11(11):1832-6. PubMed ID: 21835269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
    Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation.
    Campara M; Tzvetanov IG; Oberholzer J
    Expert Opin Biol Ther; 2010 Jun; 10(6):959-69. PubMed ID: 20415630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
    Van Gelder T; Warlé M; Ter Meulen RG
    Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.